WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Technology Software Products Friday, January 19, 2018 
Add Press Release News | News Feeds Feeds | Email This News Email

Testicular Cancer Forecast in 24 Major Markets 2018-2028
Friday, January 12, 2018

DUBLIN, Jan. 12, 2018 /PRNewswire/ --

The "Testicular Cancer Forecast in 24 Major Markets 2018-2028" report has been added to's offering.

This report provides the current incident population for testicular cancer across 24 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Denmark, Switzerland, Russia, Turkey, Saudi Arabia, South Africa, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current incidence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Testicular cancer is a relatively rare cancer; although it is the most commonly diagnosed cancer in males aged 20-34. There are two main types of testicular cancer; seminomas and non-seminomas, which develop from germ cells in the testicles. The standard treatment procedure involves the complete removal of the testis with the tumour.

Providing a value-added level of insight, several features of testicular cancer patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of testicular cancer include:

    --  Presence of lump in one testis
    --  Gynaecomastia
    --  Pain (lower back, scrotum or lower abdomen)
    --  Cryptorchidism
    --  Hypospadias

Reasons to Buy:

    --  Ability to quantify patient populations in global testicular cancer
        market to target the development of future products, pricing strategies
        and launch plans.
    --  Further insight into the incidence of the subdivided types of testicular
        cancer and identification of patient segments with high potential.
    --  Delivery of more accurate information for clinical trials in study
        sizing and realistic patient recruitment for various countries.
    --  Better understanding of the impact of specific co-morbid conditions on
        the incident population of testicular cancer patients.
    --  Identification of testicular cancer patient sub-populations that require
    --  Better understanding of the specific markets that have the largest
        number of thyroid cancer patients.

Key Topics Covered:

    1. Introduction
    2. Cause of the Disease
    3. Risk Factors & Prevention
    4. Diagnosis of the Disease
    5. Variation by Geography/Ethnicity
    6. Disease Prognosis & Clinical Course
    7. Key Comorbid Conditions / Features Associated With the Disease
    8. Methodology for Quantification of Patient Numbers
    9. Additional Data Available on Request
    10. Top-Line Incidence for Testicular Cancer
    11. Features of Testicular Cancer Patients
    12. Tumour Type
    13. Tumour Location
    14. Tumour Dissemination and Staging
    15. Clinical Parameters of Testicular Cancer Patients
    16. Comorbidities of Testicular Cancer Patients
    17. Abbreviations Used in the Report
    18. Other Services & Solutions
    19. Reports & Publications
    20. Online Epidemiology Databases
    21. Online Pharmaceutical Pricing Database
    22. References

    23. Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:

SOURCE Research and Markets

Email This News Email | Submit To Slashdot Slashdot | Submit To Digg | Submit To | News Feeds Feeds

Nav qPCR and dPCR Instrumentation Markets, 2016-2024 - Global Strategic Business Report 2018: Increasing Incidence and Prevalence of Cancer: A Grim Reality Driving Demand for qPCR and dPCR | Jan 18, 2018
Nav Vodka Must "Grow Up" or Face Continued Global Struggles - Latest Research from just-drinks and the IWSR | Jan 18, 2018
Nav New Multi-year Partnership Sees Times Higher Education Continue to Draw on Elsevier's Scopus Data for its World University Rankings | Jan 18, 2018
Nav Epson Announces Next-Generation SureColor F2100 Printer for High-Performance Direct-to-Garment Printing | Jan 18, 2018
Nav CreditPoint Software, LLC and Creditsafe Announce Integrated Risk Management Partnership | Jan 18, 2018
Nav MMR's Bruce Olson to Speak at The Quirks Event | Jan 18, 2018
Nav A New Generation of Intuitive Vendor Management Systems Is Here | Jan 18, 2018
Nav Attunity to Report Fourth Quarter and Full Year 2017 Results on February 1, 2018 | Jan 18, 2018
Nav Riffyn Opens Boston Office to Meet Accelerating Demand for Digital Transformation in Biotech and Pharmaceutical R&D | Jan 18, 2018
Nav Frost & Sullivan Recognizes Bentley Systems as a Global Provider of Customer Value for Its Future-Ready Asset Performance Management Software Solutions | Jan 18, 2018

Submit News | View More News View More News